Rivaroxaban is one of numerous new oral anticoagulants; the other direct factor Xa inhibitor in the most advanced stage of development is apixaban, and the direct thrombin inhibitor dabigatran has been licensed for use in a number of countries worldwide. A number of recent reviews describe the agents in detail, including the results of clinical trials.[67–76] All of these anticoagulants show promise and many are also being investigated for use in other indications, such as VTE treatment, acutely ill medical patients, atrial fibrillation and acute coronary syndromes. If they become licensed across this broad spectrum of indications, the armamentarium for anticoagulation available to physicians will be considerably enhanced, simplifying patient management and possibly improving outcomes with no compromise of safety compared with the established anticoagulants.
Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(3):299-306. © 2011 Expert Reviews Ltd.
Cite this: Economic Impact of Venous Thromboembolism After Hip and Knee Arthroplasty - Medscape - Jun 01, 2011.